JuLib | Articles & more - {"Langen, K. J."}

Combined FET PET/MRI radiomics differentiates radiation injury from brain metastasis recurrence

Lohmann, Philipp
2019

“...Langen, K. J....”

3

Comparison of [18F]-Fluoroethyltyrosine PET and the IDH status with Sodium MRI in Cerebral Gliomas

Shymanskaya, A.
2019

“...Langen, K. J....”

4

Comparison of [18F]-Fluoroethyltyrosine PET and the IDH status with Sodium MRI in Cerebral Gliomas

Shymanskaya, Aliaksandra
2019

“...Langen, K. J....”

5

Photopenic defects on O-(2-18F-fluoroethyl)-L-tyrosine PET - clinical relevance in glioma patients.

Galldiks, Norbert
2018

“...Langen, K. J....”

6

Hybrid MR-PET of brain tumours using amino acid PET and chemical exchange saturation transfer MRI

da Silva, N. A.
2018

European journal of nuclear medicine and molecular imaging, 45 (2018) 6, S. 1031–1040

“...Langen, K.-J....”

7

FET PET Radiomics - Differenzierung von Tumorprogression und Pseudoprogression beim Glioblastom basierend auf Texturmerkmalen

Lohmann, P.
2017

“...Langen, K. J....”

8

Prediction of progression-free survival in patients with malignant glioma using dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET

Bauer, E. K.
2017

“...Langen, K. J....”

9

Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[$^{18}$F]fluoroethyl)-L-Tyrosine PET

Kebir, S.
2016

Clinical cancer research, 22 (2016) 9, S. 2190 - 2196

“...Langen, K.-J....”

10

The predictive value of FAT and MFL for deterministic, NTMS-based fibre tracking using a multiple-ROI approach

Weiß Lucas, C.
2015

2015

“...Langen, K. J....”

11

Diagnosis of Pseudoprogression in Patients with Glioblastoma Using Amino Acid PET

Galldiks, N.
2015

2015

“...Langen, K. J....”

12

The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma

Galldiks, N.
2015

Neuro-Oncology, 17 (2015) 9, S. 1293-1300

“...Langen, K.-J....”

13

The use of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine-PET in the diagnosis of patients with progressive and recurrent glioma.

Galldiks, N.
2014

2014

“...Langen, K. J....”

14

The usefulness of dynamic O-(2-18F-Fluoroethyl)-L-Tyrosine PET in the clinical evaluation of brain tumors in childrenand adolescents.

Dunkl, V.
2015

Journal of Nuclear Medicine Journal of nuclear medicine, 56 56 (2014 2014) 1 1, S. 88-92 88-92

“...Langen, K.-J....”

15

The use of dynamic O-(2-[18F]fluoroethyl)-L-tyrosine-PET in the diagnosis of patients with progressive and recurrent glioma.

Galldiks, N.
2014

2014

“...Langen, K. J....”

16

Diagnosis of Pseudoprogression in Patients with Glioblastoma Using Amino Acid PET.

Galldiks, N.
2014

2014

“...Langen, K. J....”

17

Differentiation of local recurrent brain metastasis from radiation-induced changes using O-(2-[18F]fluoroethyl)-L-tyrosine PET.

Galldiks, N.
2014

2014

“...Langen, K.-J....”

18

Hypermetabolism in 18F-FDG PET Predicts Favorable Outcome Following Decompressive Surgery in Patients with Degenerative Cervical Myelopathy.

Floeth, F. W.
2013

Journal of nuclear medicine, 54 (2013) 9, S. 1577 - 1583

“...Langen, K. J....”

19

Assessment of treatment response in patients with glioblastoma using [18F]Fluoroethyl-L-Tyrosine PET in comparison to MRI

Galldiks, N.
2012

Journal of Nuclear Medicine Journal of nuclear medicine, 53 53 (2012 2012) 7 7, S. 1048-1057 1048-1057

“...Langen, K.J....”

20